IP Library Granted Patent US 9,073,913
Granted Patent B2
US 9,073,913 · App. 12/934,228 · Granted Jul 7, 2015

Substituted imidazoquinolines

Inventors: Volker Gekeler (Konstanz, DE); Thomas Maier (Stockach, DE); Astrid Zimmermann (Mühltal, DE); Hans-Peter Hofmann (Düsseldorf, DE); Sanjeev A. Kulkarni (Pune, IN); Anil P. Jagtap (Satara, IN); Ganesh S. Chaure (Dist-Ahmednagar, IN)
Assignee: 4SC AG
C07D471/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,073,913
App. No.
12/934,228
Granted
Jul 7, 2015
Kind
B2
Abstract

Imidazoquinolines of formula I that contain substituted amine or amide functionality at 1-position and that are effective as Toll like Receptor 7 activators are disclosed. These compounds are useful as anticancer agents.

Claims (64)

1. A compound of formula I

wherein

R 1 is selected from the group consisting of:

alkyl, alkynyl, aryl, alkoxy, heterocyclyl and heteroaryl,

which alkyl, alkynyl, aryl, alkoxy, heterocyclyl or heteroaryl is unsubstituted or substituted by one or more substituents;

A is C 1 -C 6 alkyl;

B is —N(R 2 )(R 3 );

R 2 is H or —(CO)—R 5 ;

R 5 is selected from the group consisting of:

alkyl, cycloalkyl, alkynyl, and heterocyclyl,

each of which is unsubstituted or substituted by one or more substituents;

R 3 is heterocyclyl,

which heterocyclyl is unsubstituted or substituted by one or more substituents;

or a pharmaceutically acceptable solvate, salt, N-oxide or stereoisomer thereof,

wherein at least one of the following conditions i to iv is satisfied:

i) R 2 is —(CO)—R 5 ;

ii) A is not propyl;

iii) R 1 is not butyl;

iv) R 3 does not encompass substituted piperidyl.

2. The compound of formula I according to claim 1 , wherein R 3 is heterocyclyl, which is unsubstituted or substituted by one or more substituents selected from group consisting of: —H, alkyl, alkenyl, alkoxy, halogen, —OH, —N 3 , trifluromethyl, -alkyl-aryl, —O-alkyl-aryl, —CO-aryl, aryl, heterocyclyl, heteroaryl, CO-heteroaryl, —CO-substituted aryl, CO-substituted heteroaryl, —CO—O-alkyl, —CO—N-alkyl, and —CO—N-aryl.

3. The compound of formula I according to claim 1 , wherein R 1 is selected from the group consisting of alkyl, alkynyl, aryl, alkoxy, heterocyclyl and heteroaryl, each of which is optionally substituted by one or more substituents which are selected from the group consisting of: —H, —OH, halogen, —CO—N(R 4 ) 2 , —N(R 4 ) 2 , —CO—C 1-10 alkyl, —CO—O—C 1-10 alkyl, —N 3 , optionally substituted aryl, heterocyclyl and —CO-aryl, wherein each R 4 is independently —H, —C 1-10 alkyl, —C 1-10 alkyl-aryl, or aryl.

4. The compound of formula I according to claim 1 , wherein R 5 is substituted by one or more substituents which are selected from the group consisting of: —H, —OH, halogen, —CN, —NO 2 , —COOH, —SH, —CO—C 1-6 alkyl, —CO—O—C 1-6 alkyl, —N 3 , optionally substituted aryl, heterocyclyl, —CO-aryl and —CO-heterocyclyl.

5. The compound of formula I according to claim 1 , wherein R 3 is heterocyclyl, which is unsubstituted or substituted by one or more substituents which are selected from group consisting of: —H, alkyl, alkenyl, halogen and —OH.

6. The compound of formula I according to claim 1 , wherein R 3 is selected from the group consisting of: dioxo-tetrahydrothiophenyl, tetrahydrofuranyl, tetrahydropyranyl and azabicyclooctanyl, each of which is optionally substituted by one or more groups.

7. The compound of formula I according to claim 1 , wherein R 1 is alkyl.

8. The compound of formula I according claim 1 , wherein R 5 is alkyl.

9. A compound, which is:

N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-N-(1,1-dioxidotetrahydro-3-thienyl)acetamide,

N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-N-(1-methyl-1-oxidopiperidin-4-yl)acetamide,

3-{acetyl[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]amino}-2,5-anhydro-1,3,4-trideoxypentitol,

N-[4-(4-amino-2-ethyl-1H-imidazo[4,5-c]quinolin-1-yl)butyl]-N-(1-benzyl-2-methyl-1-oxidopyrrolidin-3-yl)acetamide,

2-ethyl-1-[4-(tetrahydro-2H-pyran-4-ylamino)butyl]-1H-imidazo[4,5-c]quinolin-4-amine, 1-[4-(1-azabicyclo[2.2.2]oct-3-ylamino)butyl]-2-ethyl-1H-imidazo[4,5-c]quinolin-4-amine or 1-{4-[(1,1-dioxido-3,4-dihydro-2H-thiochromen-4-yl)amino]butyl}-2-ethyl-1H-imidazo[4,5-c]quinolin-4-amine,

or a pharmaceutically acceptable solvate, salt, N-oxide or stereoisomer thereof.

10. A pharmaceutical composition comprising a compound of formula I as claimed in claim 1 in combination with a pharmaceutically acceptable carrier.

11. A pharmaceutical composition comprising a compound of formula I as claimed in claim 1 or a pharmaceutically acceptable solvate, salt, N-oxide or stereoisomer thereof in combination with a pharmaceutically acceptable carrier sufficient to provide a dose of about 100 ng/kg to about 50 mg/kg of the compound to a subject to whom the pharmaceutical composition is administered.

12. The compound of formula I according to claim 1 , wherein R 1 is ethyl.

13. The compound of formula I according to claim 1 , wherein R 5 is methyl.

14. A compound of formula I according to claim 1 :

wherein

R 1 is selected from the group consisting of:

alkyl, alkynyl, aryl, alkoxy, heterocyclyl and heteroaryl,

which alkyl, alkynyl, aryl, alkoxy, heterocyclyl or heteroaryl is unsubstituted or substituted by one or more substituents selected from the group consisting of: —H, —OH, halogen, —CO—N(R 4 ) 2 , —N(R 4 ) 2 , —CO—C 1-10 alkyl, —CO—O—C 1-10 alkyl, —N 3 , optionally substituted aryl, heterocyclyl and —CO-aryl,

wherein each R 4 is independently —H, —C 1-10 alkyl, —C 1-10 alkyl-aryl, or aryl;

A is C 1 -C 6 alkyl;

B is —N(R 2 )(R 3 );

R 2 is H or —(CO)—R 5 ;

R 5 is selected from the group consisting of:

alkyl, cycloalkyl, alkynyl, and heterocyclyl,

each of which is unsubstituted or substituted by one or more substituents selected from the group consisting of: —H, —OH, halogen, —CN, —NO 2 , —COOH, —SH, —CO—C 1-6 alkyl, —CO—O—C 1-6 alkyl, —N 3 , optionally substituted aryl, heterocyclyl, —CO-aryl and —CO-heterocyclyl;

R 3 is heterocyclyl,

which heterocyclyl is unsubstituted or substituted by one or more substituents selected from group consisting of: —H, alkyl, alkenyl, alkoxy, halogen, —OH, —N 3 , trifluromethyl, -alkyl-aryl, —O-alkyl-aryl, —CO-aryl, aryl, heterocyclyl, heteroaryl, CO-heteroaryl, —CO-substituted aryl, CO-substituted heteroaryl, —CO—O-alkyl, —CO—N-alkyl, and —CO—N-aryl;

or a pharmaceutically acceptable solvate, salt, N-oxide or stereoisomer thereof, wherein at least one of the following conditions i to iv is satisfied:

i) R 2 is —(CO)—R 5 ;

ii) A is not propyl;

iii) R 1 is not butyl;

iv) R 3 is not substituted piperidyl.

15. The compound of formula I according to claim 1 , wherein only condition ii) is satisfied.

16. The compound of formula I according to claim 1 , wherein only condition iii) is satisfied.

17. The compound of formula I according to claim 1 , wherein only condition iv) is satisfied.

18. The compound of formula I according to claim 1 , wherein only condition i) is satisfied.

19. The compound of formula I according to claim 1 , or a pharmaceutically acceptable salt thereof.

20. The compound of claim 9 , or a pharmaceutically acceptable salt thereof.

21. The compound of formula I according to claim 1 , wherein R 2 is H.

22. The compound of formula I according to claim 14 , wherein R 2 is H.

Assignments (3)
CHANGE OF NAME Recorded Aug 16, 2019
From: BIONTECH AG
To: BIONTECH SE
Reel/Frame 050082/0342 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 4, 2018
From: 4SC AG
To: BIONTECH AG
Reel/Frame 046780/0072 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 15, 2011
From: GEKELER, VOLKER; MAIER, THOMAS; ZIMMERMANN, ASTRID; HOFMANN, HANS-PETER; KULKARNI, SANJEEV A.; JAGTAP, ANIL P.; CHAURE, GANESH S.
To: 4SC AG
Reel/Frame 026459/0546 →
Priority Claims (1)
IN 614/MUM/2008 · Mar 24, 2008 · national
Continuity (1)
Related Publication 20110245289A1 · Oct 6, 2011